Abstract
Personalising cancer therapy is a way of improving treatment efficacy, by selecting specific treatments for patients with certain molecular changes to their tumour. This requires both molecular material to detect these targets and a preclinical disease model to demonstrate treatment efficacy. In pancreatic cancer this is problematic, as most patients present with advanced disease and are therefore ineligible for surgery. As a result, biological material derived from such patients has been excluded from all preclinical studies in personalised medicine. This chapter presents methodology to achieve both of the above-mentioned requirements using endoscopic ultrasound-guided fine-needle aspiration, which can be offered to nearly all patients with early or advanced disease.
| Original language | English |
|---|---|
| Title of host publication | Inflammation and Cancer |
| Subtitle of host publication | Methods and Protocols |
| Editors | Brendan J. Jenkins |
| Publisher | Humana Press |
| Pages | 31-40 |
| Number of pages | 10 |
| ISBN (Electronic) | 9781493975686 |
| ISBN (Print) | 9781493975679 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Volume | 1725 |
| ISSN (Print) | 1064-3745 |
| ISSN (Electronic) | 1940-6029 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- EUS-FNA
- NOD-SCID mice
- Oncology
- Pancreatic cancer
- Personalised therapy
- RNA
- RNAseq
- Target therapy
- Xenograft
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver